“Delay to TKA in Patients Treated with a Multimodal Approach using High Molecular Weight, Biologically Derived Hyaluronic Acid”

BHIPeer Reviewed Articles

The Journal of Long-Term Effects of Medical Implants, March 2021 The primary objective of this study was to determine the effect of single versus multiple rounds of intra-articular hyaluronic acid (IA-HA) in delaying the need for total knee arthroplasty (TKA) in patients with knee OA, and if additional benefits were seen when used in conjunction with other multimodal treatment options. Methods … Read More

“Delay to TKA and Costs Associated with Knee Osteoarthritis Care Using Intra-Articular Hyaluronic Acid: Analysis of an Administrative Database”

BHIPeer Reviewed Articles

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, March 2021 The primary objective of this study was to examine the relationship between intra-articular hyaluronic acid (IA-HA) treatment and delaying TKA in patients with KOA compared to patients not receiving IA-HA, as well as to identify differences in KOA-related costs incurred among patients who received or did not receive IA-HA.

“Knee OA cost comparison for hyaluronic acid and knee arthroplasty”

BHIPeer Reviewed Articles

Journal of Orthopaedic Surgery and Research, August 2020 Limiting treatment to those recommended by the American Academy of Orthopaedic Surgeon Clinical Practice Guidelines has been suggested to decrease costs by 45% in the year prior to total knee arthroplasty, but this only focuses on expenditures leading up to, but not including, the surgery and not the entire episode of care. BHI’s … Read More

“Medical Utilization Surrounding Initial Opioid-Related Diagnoses by Coding Method”

BHIPeer Reviewed Articles

The American Journal of Managed Care, February 2020 A budget impact analysis was conducted from a U.S. commercial payer perspective over a 1-year time horizon with patients who received the implant or revision ESS. Primary outcomes of interest were annual total and per-member per-month (PMPM) direct health care costs. Costs were estimated using a decision analysis model, assuming 50% implant … Read More

“Lymphedema-associated comorbidities and treatment gap”

BHIPeer Reviewed Articles

Journal of Vascular Surgery: Venous and Lymphatic Disorders, September 2019 To determine the proportion of LE patients with various LE-associated comorbidities as well as the rate of associated treatment, deidentified Health Insurance Portability and Accountability Act-compliant commercial administrative claims from the Blue Health Intelligence® (BHI®) research database (165 million Blue Cross Blue Shield members) were queried. We analyzed a BHI … Read More

“Budget Impact of a Steroid-Eluting Sinus Implant Versus Sinus Surgery for Adult Chronic Sinusitis Patients with Nasal Polyps”

BHIPeer Reviewed Articles

Journal of Managed Care & Specialty Pharmacy, August 2019 A budget impact analysis was conducted from a U.S. commercial payer perspective over a 1-year time horizon with patients who received the implant or revision ESS. Primary outcomes of interest were annual total and per-member per-month (PMPM) direct health care costs. Costs were estimated using a decision analysis model, assuming 50% … Read More

“The Influence of Physician Payments on the Method of Breast Reconstruction”

BHIPeer Reviewed Articles

Journal of the American Society of Plastic Surgeons, October 2018 Using the Blue Health Intelligence® database from 2009 to 2013, patients were identified who underwent tissue expander (i.e., implant) or free-flap breast reconstruction. The implant-to-flap ratio and physician payments were assessed using quadratic modeling. Matched bootstrapped samples from the early and late periods generated probability distributions, approximating the odds of … Read More

“Benefits of Advanced Pneumatic Compression Devices in Patients with Phlebolymphedema”

BHIPeer Reviewed Articles

Journal of Vascular Surgery, June 2018 This was a longitudinal matched case-control analysis of deidentified private insurance claims. The study used administrative claims data from Blue Health Intelligence® for the complete years 2012 through 2016. Patients were continuously enrolled for at least 18 months, diagnosed with phlebolymphedema, and received at least one claim for CONS either alone or in addition … Read More